Eppendorf says it will continue investing in production capabilities and infrastructure as it reports a record 12 months. German life sciences tool provider Eppendorf reported revenues of €967 million($1.16 billion) for its fiscal year 2020, up 20.3% on the year prior. “2020 was by far the most successful fiscal year for the Eppendorf Group,” co-CEOs Eva van Pelt and Peter Fruhstorfer said in a joint statement. Like many of its fellow bioprocess suppliers, growth in sales across many of Eppendorf’s…

Avantor says investments in facilities in North Carolina, Massachusetts, and The Netherlands will help feed the surge in demand for single-use equipment driven by a robust biologics sector and the COVID-19 pandemic. Sean DeFusco, general manager of single-use solutions/fluid handling at Avantor, told BioProcess Insider the firm will increase its single-use manufacturing footprint by 30% in the United States and Europe along with doubling cleanroom space. “So far, we expanded our Morrisville, North Carolina single-use facility and we’re nearing completion…

Some biomanufacturers are waiting up to a year for single-use equipment, according to ABEC. And while vendors are expanding capacity these projects will take months to come online. Early in the COVID-19 pandemic, single-use bioprocess systems and materials were highlighted as necessary tools in the development and commercial manufacture of potential vaccines and therapies. The speed and flexibility needed to make novel vaccines, including mRNA, DNA, and viral vectors, meant those platforms were largely built on single-use technologies. Coupled with…

Danaher expects COVID-19 vaccine and therapy-related revenue for its bioprocess businesses Pall and Cytiva to reach $2 billion, while the pandemic fuelled “an exceptionally strong start” to Sartorius’s 2021. In June last year, the evolving coronavirus pandemic was marked out as a $14 billion opportunity for bioprocess vendors by analysts. Ten months on, with several vaccines and therapies being used commercially and several more moving through the clinic, the service firms are experiencing unprecedented demand for their equipment and tools…

The coronavirus pandemic has underlined the benefits of modular manufacturing according to an expert who says the approach has been key to accelerating vaccine production. SARS-CoV-2, the virus that causes COVID-19, was first isolated in December 2019 and sequenced a month later. The first vaccines against it were developed, tested, and approved about a year after the first was identified. The record speed with which industry created the COVID-19 shots is testament to vaccine industry efforts, according to John Yoshi…